Measurement of 17-Alpha Hydroxyprogesterone on a State-of-the-Art ABEI-Based Chemiluminescence System Establishment of Upper Reference Limit

Research Article

J Pediatr Endocrinol. 2025; 10(1): 1069.

Measurement of 17-Alpha Hydroxyprogesterone on a State-of-the-Art ABEI-Based Chemiluminescence System – Establishment of Upper Reference Limit

Ijaz A¹*, Sahar R², Javed B², Ahmed F³, Najeeb S², Shahid F² and Hafeez N²

1NUST School of Health Sciences, Islamabad, Pakistan

2Mohi Uddin Islamic Medical College and Hospital, Mirpur, AJ&K, Pakistan

3Milton-Keyenes University Hospital, NHS Trust, Oxford University Hospitals, UK

*Corresponding author: Prof Aamir Ijaz, NUST School of Health Sciences, National University of Science and Technology (NUST), Islamabad, Pakistan Email: aamirijaz@nshs.nust.edu.pk

Received: February 17, 2025; Accepted: March 10, 2025; Published: March 13, 2025;

Abstract

Background: 17 alpha Hydroxyprogesterone (17a-OHP) is the most commonly used test for the screening and diagnosis of congenital adrenal hyperplasia in neonates. Establishment of Upper Reference Limit (URL) of 17a-OHP using an ABEI-Based chemiluminescence autoanalysers has been done for the first time in Pakistan.

Methods and Materials: Out of 187 neonates included in the study, serum specimens of 139 disease-free neonates (<30 days of age) were collected in Mohi Uddin Teaching Hospital Mirpur AJ&K (MOTH) after taking consent from the mothers of the kids. Excluding ten haemolysed specimens, 129 samples were analyzed in the Pathology Laboratory of MOTH using Maglumi X8 (Snibe, Shenzhen, China), an ABEI (N-(aminobutil)-N-(ethyl)-isoluminol)-based system. Three results were declared outliers, rest were used for calculation of URL of 17a-OHP.

Results: The 99th Percentile URL of 17-OHP was found to be 4.7 nmol/L in 126 samples

Conclusion: A cut-off value of 4.7 nmol/L (156 ng/dl) can be used for the exclusion of congenital adrenal hyperplasia in Pakistan Children

Keywords: Congenital adrenal hyperplasia; 17 Hydroxyprogesterone; 21 Hydroxylase deficiency

Introduction

Congenital Adrenal Hyperplasia (CAH) is a complex and often life-threatening disease with a multitude of hormonal imbalances that can result in disease-and treatment-related adverse outcomes [1]. Markedly raised 17-alpha hydroxyprogesteron (17a-OHP) is pathognomonic of congenital adrenal hyperplasia (CAH) in neonates. The steroid 17-a-OHP) is produced by both the adrenal cortex and gonads [2]. Even though 17a-OHP has relatively little progestational activity, it is of intense clinical interest because it is the immediate precursor to 11-desoxycortisol (11-DOC). 11-DOC is produced by 21-hydroxylation of 17-a-OHP (Figure 1), measurement of 17-a-OHP is a useful indirect indicator of 21-hydroxylase activity [3]. A deficiency of 21-hydroxylase (21OH) leads to accumulation of proximal metabolite i.e. 17-OHP, which has an androgenic action. Cortisol deficiency does not occur due to increased ACTH causing adrenal hyperplasia and near normalisation of cortisol [4]. These neonates may present with salt-losing wasting (both genders) or ambiguous genitalia (girls) [5]. Deficiency of 21-OHD accounts for 95 percent of cases of CAH [4]. About 200 gene mutations in CYP21A2 are involved in causation of a continuum of disease phenotypes and the expected residual 21-OHD activity with each genotype [6]. CAH is included in the mandatory newborn screening programmes of many developed countries [7]. Prevalence of 21-OHD has been found to be approximately 6.5 million livebirths [8], an overall prevalence of approximately 1 in 15,000 livebirths [9,10]. Traditionally, radioimmunoassay (RIA) has been used for the measurement of 17a-OHP [11] but RIA has numerous disadvantages and limitations [12]. So chemiluminescence immunoassay (CLIA) has now been made available for estimation of 17a-OHP [13]. CLIA has the biggest advantage of ultra-high analytical sensitivity and ease of automation [14].